[go: up one dir, main page]

PE20161388A1 - Inhibidores de la jak1 para el tratamiento de sindromes mielodisplasicos - Google Patents

Inhibidores de la jak1 para el tratamiento de sindromes mielodisplasicos

Info

Publication number
PE20161388A1
PE20161388A1 PE2016001538A PE2016001538A PE20161388A1 PE 20161388 A1 PE20161388 A1 PE 20161388A1 PE 2016001538 A PE2016001538 A PE 2016001538A PE 2016001538 A PE2016001538 A PE 2016001538A PE 20161388 A1 PE20161388 A1 PE 20161388A1
Authority
PE
Peru
Prior art keywords
pyrrolo
treatment
pyrazol
pyrimidin
jak1
Prior art date
Application number
PE2016001538A
Other languages
English (en)
Inventor
Krishna Vaddi
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of PE20161388A1 publication Critical patent/PE20161388A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se refiere a un metodo para tratar un sindrome mielodisplasico que comprende administrar a un paciente un compuesto derivado de pirrolo[2,3-d]pirimidina o pirrolo[2,3-b]piridina que inhiben selectivamente la quinasa Janus 1 (JAK1), donde el compuesto es seleccionado de 3-[1-(6-cloropiridin-2-il)pirrolidin-3-il]-3-[4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propanonitrilo, 3-[1-(1,3]oxazolo[5,4-b]piridin-2ilpirrolidin-3-il)-3-[4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]propanonitrilo o sales farmaceuticamente aceptables de los mismos. Los sindromes mielodisplasicos son citopenia refractaria con displasia unilinaje (RCUD), anemia refractaria con sideroblastos en anillo (RARS), entre otros
PE2016001538A 2014-02-28 2015-02-27 Inhibidores de la jak1 para el tratamiento de sindromes mielodisplasicos PE20161388A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461946124P 2014-02-28 2014-02-28

Publications (1)

Publication Number Publication Date
PE20161388A1 true PE20161388A1 (es) 2016-12-28

Family

ID=52693052

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016001538A PE20161388A1 (es) 2014-02-28 2015-02-27 Inhibidores de la jak1 para el tratamiento de sindromes mielodisplasicos

Country Status (29)

Country Link
US (4) US20150246046A1 (es)
EP (1) EP3110409B1 (es)
JP (1) JP6576941B2 (es)
KR (1) KR20160136323A (es)
CN (2) CN106456773A (es)
AU (1) AU2015222913B2 (es)
CA (1) CA2940659C (es)
CL (1) CL2016002144A1 (es)
CR (1) CR20160449A (es)
CY (1) CY1120857T1 (es)
DK (1) DK3110409T3 (es)
EA (1) EA201691745A1 (es)
ES (1) ES2688553T3 (es)
HR (1) HRP20181661T1 (es)
HU (1) HUE041456T2 (es)
IL (1) IL247475B (es)
LT (1) LT3110409T (es)
MX (1) MX372939B (es)
MY (1) MY185392A (es)
PE (1) PE20161388A1 (es)
PL (1) PL3110409T3 (es)
PT (1) PT3110409T (es)
RS (1) RS57723B1 (es)
SG (2) SG10201807952PA (es)
SI (1) SI3110409T1 (es)
SM (1) SMT201800551T1 (es)
UA (1) UA121857C2 (es)
WO (1) WO2015131031A1 (es)
ZA (1) ZA201606610B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2343298B9 (en) 2005-12-13 2020-05-06 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
RS53245B2 (sr) 2007-06-13 2022-10-31 Incyte Holdings Corp Soli inhibitora janus kinaze (r)-3-(4-(7h-pirolo(2,3-d) pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropan-nitrila
HRP20192203T1 (hr) 2009-05-22 2020-03-06 Incyte Holdings Corporation 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]oktan- ili heptan-nitril kao jak inhibitori
SI3354652T1 (sl) 2010-03-10 2020-08-31 Incyte Holdings Corporation Derivati piperidin-4-il azetidina kot inhibitorji JAK1
MY161078A (en) 2010-05-21 2017-04-14 Incyte Holdings Corp Topical formulation for a jak inhibitor
JP5917545B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体
PE20140832A1 (es) * 2011-06-20 2014-07-14 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CA2888816A1 (en) 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
TWI702057B (zh) 2012-11-15 2020-08-21 美商英塞特控股公司 盧梭利替尼之緩釋性劑型
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
ES2790419T3 (es) 2013-01-15 2020-10-27 Incyte Holdings Corp Los compuestos de tiazolcarboxamidas y piridinacarboxamida útiles como inhibidores de quinasa de PIM
ES2900492T3 (es) 2013-03-06 2022-03-17 Incyte Holdings Corp Procesos y productos intermedios para elaborar un inhibidor de JAK
PL3786162T3 (pl) 2013-05-17 2024-04-08 Incyte Holdings Corporation Pochodne bipirazolu jako inhibitory jak
RS60469B1 (sr) 2013-08-07 2020-07-31 Incyte Corp Dozni oblici sa produženim oslobađanjem za jak1 inhibitor
US9556197B2 (en) 2013-08-23 2017-01-31 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
LT3129021T (lt) 2014-04-08 2020-12-10 Incyte Corporation B ląstelių piktybiškumo gydymas jak ir pi3k inhibitorių deriniu
MA39987A (fr) 2014-04-30 2017-03-08 Incyte Corp Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
KR101960592B1 (ko) * 2016-03-09 2019-03-21 울산대학교 산학협력단 Jak1 억제제를 유효성분으로 포함하는 줄기세포의 증식, 분화 촉진 또는 노화 억제용 조성물
KR101934107B1 (ko) * 2016-12-15 2018-12-31 가톨릭대학교산학협력단 골수형성이상 증후군 환자의 저메틸화 제제 치료 반응성 및 생존 예후 예측용 조성물
CN108341820B (zh) 2017-01-23 2020-10-16 上海长森药业有限公司 Jak酶抑制剂及其制备方法和用途
CN109867676B (zh) * 2017-12-01 2020-10-30 北京普祺医药科技有限公司 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途
TW201924683A (zh) 2017-12-08 2019-07-01 美商英塞特公司 用於治療骨髓增生性贅瘤的低劑量組合療法
PT3746429T (pt) 2018-01-30 2022-06-20 Incyte Corp Processos para a preparação de (1-(3-fluoro-2-(trifluorometil)isonicotinoíl)piperidin-4-ona)
EP4085965A1 (en) 2018-02-01 2022-11-09 Shifamed Holdings, LLC Intravascular blood pumps and methods of use and manufacture
BR122023022189A2 (pt) 2018-02-16 2024-02-20 Incyte Corporation Usos de inibidores da via de jak1 para o tratamento de distúrbios relacionados a citocinas
JP7565798B2 (ja) 2018-03-30 2024-10-11 インサイト・コーポレイション 炎症性皮膚疾患のバイオマーカー
EP4424328A3 (en) 2018-03-30 2024-12-04 Incyte Corporation Treatment of hidradenitis suppurativa using jak inhibitors
CA3097025A1 (en) 2018-04-13 2019-10-17 Incyte Corporation Biomarkers for graft-versus-host disease
IL278889B2 (en) 2018-06-01 2025-11-01 Incyte Corp Dosing regimen for the treatment of pi3k related disorders
CN120960440A (zh) * 2018-10-31 2025-11-18 斯坦林治疗公司 用白喉毒素-人白细胞介素-3缀合物与其它药剂组合治疗骨髓增生性肿瘤的组合治疗方法
EP3873433A1 (en) * 2018-10-31 2021-09-08 Incyte Corporation Combination therapy for treatment of hematological diseases
CN111320633B (zh) * 2018-12-14 2022-09-27 中国医药研究开发中心有限公司 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途
MA55201A (fr) * 2019-03-05 2022-01-12 Incyte Corp Inhibiteurs de la voie jak1 pour le traitement d'un dysfonctionnement chronique de l'allogreffe pulmonaire
WO2021062163A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
US12360120B2 (en) 2019-10-10 2025-07-15 Incyte Corporation Biomarkers for graft-versus-host disease
JP2022551649A (ja) 2019-10-10 2022-12-12 インサイト・コーポレイション 移植片対宿主病のバイオマーカー
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
CN111358791A (zh) * 2020-03-13 2020-07-03 深圳百奥捷生物科技有限公司 Jak/stat信号通路磷酸盐抑制剂在制备治疗dba疾病的药物中的应用
HRP20241560T1 (hr) 2020-06-02 2025-01-17 Incyte Corporation Postupci za proizvodnju inhibitora jak1
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
IL303238A (en) 2020-12-08 2023-07-01 Incyte Corp Jak1 pathway inhibitors for the treatment of vitiligo
JP2024503372A (ja) * 2021-01-18 2024-01-25 アクティブ バイオテック エイビー 骨髄異形成症候群の処置における使用のためのタスキニモドまたはその薬学的に許容される塩
TW202308610A (zh) 2021-05-03 2023-03-01 美商英塞特公司 用於治療結節性癢疹之ｊａｋ１途徑抑制劑
CN121399112A (zh) * 2023-04-27 2026-01-23 维泰瑞隆有限公司 Sarm1调节剂、其制备和用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
ES2342240T3 (es) 1998-08-11 2010-07-02 Novartis Ag Derivados de isoquinolina con actividad que inhibe la angiogenia.
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
KR100786927B1 (ko) 2000-06-28 2007-12-17 스미스클라인비이참피이엘시이 습식 분쇄방법
HUP0401982A3 (en) 2001-09-19 2012-09-28 Aventis Pharma Sa Indolizine derivates, process for their preparation and pharmaceutical compositions containing the compounds
HU230798B1 (hu) 2001-10-30 2018-06-28 Novartis Ag Staurosporin-származékok mint az FLT3 receptor tirozin-kináz aktivitás inhibitorai
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
AR045944A1 (es) 2003-09-24 2005-11-16 Novartis Ag Derivados de isoquinolina 1.4-disustituidas
MX2007006204A (es) 2004-11-24 2007-06-20 Novartis Ag Combinaciones que comprenden inhibidores de jak y cuando menos uno de entre inhibidores de bcr-abl, flt-3, fak o raf cinasa.
TW200635899A (en) 2004-12-22 2006-10-16 Astrazeneca Ab Chemical compounds
EP2343298B9 (en) * 2005-12-13 2020-05-06 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
MY165582A (en) 2008-03-11 2018-04-05 Incyte Holdings Corp Azetidine and cyclobutane derivatives as jak inhibitors
WO2010135650A1 (en) 2009-05-22 2010-11-25 Incyte Corporation N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
SI3354652T1 (sl) * 2010-03-10 2020-08-31 Incyte Holdings Corporation Derivati piperidin-4-il azetidina kot inhibitorji JAK1
JP5917545B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としてのシクロブチル置換ピロロピリジンおよびピロロピリミジン誘導体
WO2012068440A1 (en) * 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
AU2011335882B2 (en) * 2010-12-03 2016-03-10 Ym Biosciences Australia Pty Ltd Treatment of JAK2-mediated conditions
PE20140832A1 (es) 2011-06-20 2014-07-14 Incyte Corp Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
US9193733B2 (en) 2012-05-18 2015-11-24 Incyte Holdings Corporation Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
US10155987B2 (en) * 2012-06-12 2018-12-18 Dana-Farber Cancer Institute, Inc. Methods of predicting resistance to JAK inhibitor therapy
CA2888816A1 (en) * 2012-11-01 2014-05-08 Incyte Corporation Tricyclic fused thiophene derivatives as jak inhibitors
PL3786162T3 (pl) * 2013-05-17 2024-04-08 Incyte Holdings Corporation Pochodne bipirazolu jako inhibitory jak

Also Published As

Publication number Publication date
EP3110409B1 (en) 2018-08-15
CN106456773A (zh) 2017-02-22
EP3110409A1 (en) 2017-01-04
MY185392A (en) 2021-05-17
CA2940659C (en) 2023-01-03
BR112016019511A8 (pt) 2023-01-24
AU2015222913A1 (en) 2016-09-29
US20150246046A1 (en) 2015-09-03
US20190111058A1 (en) 2019-04-18
CN112494652A (zh) 2021-03-16
RS57723B1 (sr) 2018-12-31
NZ724464A (en) 2021-01-29
AU2015222913B2 (en) 2019-12-12
KR20160136323A (ko) 2016-11-29
ZA201606610B (en) 2020-08-26
BR112016019511A2 (es) 2017-08-15
SI3110409T1 (sl) 2018-11-30
DK3110409T3 (en) 2018-10-22
SG11201607083VA (en) 2016-09-29
EA201691745A1 (ru) 2016-12-30
ES2688553T3 (es) 2018-11-05
HUE041456T2 (hu) 2019-05-28
CY1120857T1 (el) 2019-12-11
PT3110409T (pt) 2018-11-07
MX2016011103A (es) 2017-02-28
US20220378791A1 (en) 2022-12-01
PL3110409T3 (pl) 2018-12-31
JP6576941B2 (ja) 2019-09-18
CL2016002144A1 (es) 2016-12-16
US20210069193A1 (en) 2021-03-11
CR20160449A (es) 2016-12-20
MX372939B (es) 2020-04-03
HRP20181661T1 (hr) 2018-12-14
IL247475B (en) 2020-05-31
SG10201807952PA (en) 2018-10-30
JP2017506659A (ja) 2017-03-09
UA121857C2 (uk) 2020-08-10
IL247475A0 (en) 2016-11-30
CA2940659A1 (en) 2015-09-03
WO2015131031A1 (en) 2015-09-03
LT3110409T (lt) 2019-01-25
SMT201800551T1 (it) 2019-01-11

Similar Documents

Publication Publication Date Title
PE20161388A1 (es) Inhibidores de la jak1 para el tratamiento de sindromes mielodisplasicos
NI202000072A (es) Derivados de 2-amino-piridina o 2-amino-pirimidina como inhibidores de cinasa dependientes de ciclina
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
EA201890001A1 (ru) Замещенные гетероциклические производные как ингибиторы циклинзависимой киназы (cdk)
SI3523301T1 (sl) Substituirane spojine pirazolo(1,5-A)piridina kot inhibitorji RET kinaze
SI3523302T1 (sl) Substituirane spojine pirazolo(1,5-A)piridina kot inhibitorji ret kinaze
UY35834A (es) Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon
CL2014001529A1 (es) Compuestos pirazolo[1,5-a]piridina suistituidos, inhibidores del receptor de tropomiosina quinasa (trk); composicion farmaceutica que los comprende; metodo de inhibicion del recetor de tropomiosina quinasa a (trka); y metodo de tratamiento o prevencion del dolor, cancer, restenosis y aterosclerosis, entre otras enfermedades.
UY35675A (es) Derivados sustituidos de quinazolin-4-ona
WO2016142855A3 (en) Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
SI3322706T1 (sl) Substituirane pirazolo(1,5-A)piridinske spojine kot zaviralci ret-kinaze
MX347040B (es) Inhibidores de tirosina-cinasas.
CU20150078A7 (es) Derivados de cicloalquilo pirrolo [2, 3-d]pirimidina -4-il amino útiles como inhibidores de quinasas janus relacionadas y composiciones farmacéuticas que contienen tales compuestos
MX381053B (es) Formas cristalinas de las sales del compuesto 5-(((1r,1as,6br)-1-(6-(trifluorometil)-1h-benzo[d]imidazol-2-il)-1a,6b-dihidro-1h-ciclopropa [b] benzofuran-5-il) oxi)-3,4-dihidro-1,8-naftiridin-2(1h)-ona, sus métodos de preparación sus usos de las mismas.
PE20170523A1 (es) Formulacion en forma de tableta de 2-fluor-n-metil-4-[7-(quinolin-6-ylmetil)imidazo[1,2- b][1,2,4]triazin-2-il]benzamida
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
MY194104A (en) Azabenzimidazoles and their use as ampa receptor modulators
PL3357922T3 (pl) Pochodne 2-((5-(1-(3-(metylosulfonylo)propylo)piperydyn-4-ylo)pirydyn-2-ylo)amino)pirydo[2,3-d]pirymidyn-7(8h)-onu i związki pokrewne jako inhibitory cdk4 do leczenia nowotworów
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
NZ736055A (en) Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
EA202091761A1 (ru) Комбинированная терапия для лечения гастроинтестинальных стромальных опухолей
CL2016000496A1 (es) Compuestos derivados de 1,2,4-triazolo[1,5-a]-piridina, inhibidores de una janus cinasa, tal como jak1; composiciones farmacológicas; útiles para el tratamiento de enfermedades inflamatorias.
MX379000B (es) Proceso para preparar inhibidores de tirosina cinasa de bruton (btk).
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
CO2019002171A2 (es) Compuestos 8-(azetidín-1-il)-[1,2,4]triazolo[1,5-a]piridinilo, composiciones y métodos de utilización de los mismos.